Article Listing - US FDA suspends generic oxaliplatin after legal action from Sanofi-Aventis

MORE EXPANSION AT CHILE'S LABS SAVAL

23 March 1992

Laboratorios Saval of Santiago in Chile, which is the third largest drugmaker in the ranking compiled by the national and...

CHILE'S PROFARMA SEEKING DEALS

23 March 1992

Laboratorios Profarma is one of Chile's smaller national pharmaceutical companies, but its size is not indicative of its importance in...

COMPARATIVE STUDY CALL WITH ZOFRAN

23 March 1992

Glaxo's 5-HT3 receptor antagonist anti-emetic Zofran (ondansetron) represents a great improvement on earlier anti-emetics for chemotherapy regimens that include cisplatin,...

MEDEVA ACQUIRES HEP-B PRODUCTS

23 March 1992

UK pharmaceuticals group Medeva is continuing its program of buying and developing pharmaceutical products with short development times with the...

GENENTECH'S DNase IN CYSTIC FIBROSIS

23 March 1992

Genentech's recombinant human deoxyribonuclease I (DNase) has been found to be safe in the treatment of cystic fibrosis patients. And...

SCHERER/FABRE DRUG DELIVERY ACCORD

23 March 1992

Pierre Fabre of France and US-based R P Scherer have entered into a collaborative agreement targeted at the development and...

DANISH COMPLAIN OVER GLAXO PRICING

23 March 1992

Oral use of Pfizer's triazole antifungal Diflucan (fluconazole) has been deemed superior to weekly intravenous injections of amphotericin B to...

GAMBRO PRETAX EARNINGS JUMP 46%

16 March 1992

Swedish company Gambro reported sales up 12.9% to 5.62 billion Swe-dish kroner ($943.8 million) for 1991, and pretax earnings of...

MEVACOR WORKS IN FDB, SAYS STUDY

16 March 1992

Familial defective apolipoprotein B-100 (FDB), an autosomal dominant disorder characterized by hyper-cholesterolemia, has been shown to be responsive to treatment...

HANTAREX BIOMED LINK WITH SMA?

16 March 1992

A new alliance with possible developments in the biomedical sector has been set up recently in Italy. Under a preliminary...

Showing 94821-94830 of 95579 articles

Go to beginningPreviousNextGo to end